Protara Therapeutics Files 8-K on Shareholder Matters

TL;DR

Protara Therapeutics filed an 8-K on June 7th regarding shareholder votes. Standard corporate update.

AI Summary

Protara Therapeutics, Inc. filed an 8-K on June 10, 2024, reporting on matters submitted to a vote of security holders as of June 7, 2024. The filing details the company's corporate structure, including its state of incorporation (Delaware) and IRS Employer Identification Number. It also lists the company's principal executive offices located at 345 Park Avenue South, New York, NY.

Why It Matters

This filing provides an update on corporate governance and administrative matters for Protara Therapeutics, Inc., which is important for investors to track company operations and compliance.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new financial or operational risks.

Key Players & Entities

• Protara Therapeutics, Inc. (company) — Registrant
• June 7, 2024 (date) — Date of earliest event reported
• June 10, 2024 (date) — Date of Report
• Delaware (jurisdiction) — State of incorporation
• 345 Park Avenue South, Third Floor, New York, NY 10010 (address) — Address of principal executive offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share TARA The Nasdaq Capital M

Filing Documents

• ea0207579-8k_protara.htm (8-K) — 39KB
• 0001213900-24-051210.txt ( ) — 209KB
• tara-20240607.xsd (EX-101.SCH) — 3KB
• tara-20240607_lab.xml (EX-101.LAB) — 33KB
• tara-20240607_pre.xml (EX-101.PRE) — 22KB
• ea0207579-8k_protara_htm.xml (XML) — 4KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. The Annual Meeting of Stockholders (the "Annual Meeting") of Protara Therapeutics, Inc. (the "Company") was held on June 7, 2024. As of April 11, 2024, the record date for the Annual Meeting, there were 20,578,425 shares of the Company's common stock outstanding and entitled to vote. A summary of the matters voted upon at the Annual Meeting and the final voting results are set forth below. Proposal 1. Election of Directors. The Company's stockholders elected the three persons listed below as Class I directors, each to serve on the Company's Board of Directors until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes Jane Huang, M.D. 9,656,095 125,127 3,809,729 Richard Levy, M.D. 9,642,092 139,130 3,809,729 Michael Solomon, Ph.D. 9,560,752 220,470 3,809,729 Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm. The Company's stockholders ratified the selection by the Company's Audit Committee of the Board of Ernst and Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The final voting results are as follows: Votes For Votes Against Abstentions 13,399,953 189,574 1,424 Proposal 3. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers. The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's definitive proxy Votes For Votes Against Abstentions Broker Non-Votes 6,999,091 196,457 2,585,674 3,809,729 Proposal 4. Approval of the Protara Therapeutics, Inc. 2024 Equity Incentive Plan. The Company's

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Protara Therapeutics, Inc. Dated: June 10, 2024 By: /s/ Patrick Fabbio Patrick Fabbio Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR